PHWA
REGN icon

Petersen Hastings Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Petersen Hastings Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
381
+1
+0.3% +$681 0.02% 77
2026
Q1 		$294K Hold
380
– – 0.03% 64
2025
Q4 		$293K Buy
+380
New +$258K 0.03% 64

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Petersen Hastings Wealth Advisors's REGN Position: Q2 2026 in Review

Petersen Hastings Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.26% in Q2 2026, buying an estimated $681 and bringing the position to 381 shares worth $238K. The position accounts for 0.02% of the portfolio, ranked #77.

Petersen Hastings Wealth Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $294K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Petersen Hastings Wealth Advisors held 381 shares of Regeneron Pharmaceuticals worth $238K as of Q2 2026.
  • Petersen Hastings Wealth Advisors bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
  • Regeneron Pharmaceuticals made up 0.02% of Petersen Hastings Wealth Advisors's portfolio in Q2 2026, its #77 holding.
  • Petersen Hastings Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Petersen Hastings Wealth Advisors's Regeneron Pharmaceuticals position peaked at $294K in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Petersen Hastings Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.